Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (617)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07411586 | Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia | active not recruiting | Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07779031 | A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT(TP53) | active not recruiting | Phase 1 / Phase 2 | 58 | Liping DouOTHER | 1 | Aug 21, 2026 |
| clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT02835222 | Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients | active not recruiting | Phase 2 | 57 | Wake Forest University Health SciencesOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05796570 | A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies(MORE) | active not recruiting | Phase 2 | 29 | Franziska WachterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02521493 | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | active not recruiting | Phase 3 | 280 | Children's Oncology GroupNETWORK | 6 | Aug 19, 2026 | clinicaltrials |
| NCT03147612 | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03906292 | Frontline Asciminib Combination in Chronic Phase CML(CMLXI) | active not recruiting | Phase 2 | 125 | University of JenaOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06001385 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis(OPTIMIZE) | active not recruiting | Phase 2 | 313 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04013685 | Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | active not recruiting | Phase 1 | 155 | Orca Biosystems, Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04537871 | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study | active not recruiting | — | 350 | City of Hope Medical CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05150561 | Muscle Dysfunction in Patients With Haematological Diseases | active not recruiting | — | 216 | Rigshospitalet, DenmarkOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05428176 | A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors | active not recruiting | N/A | 332 | City of Hope Medical CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05457010 | Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS | active not recruiting | Phase 1 | 24 | Arcellx, Inc.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03503409 | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | active not recruiting | Phase 2 | 68 | Groupe Francophone des MyelodysplasiesOTHER | 2 | Aug 10, 2026 | clinicaltrials |
| NCT00392353 | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 135 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02861417 | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 204 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03253848 | Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia | active not recruiting | N/A | 202 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT06456463 | A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy(TRILLIUM) | active not recruiting | Phase 2 | 85 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
| NCT04975919 | Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05457556 | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | active not recruiting | Phase 3 | 66 | Children's Oncology GroupNETWORK | 3 | Jul 30, 2026 | clinicaltrials |
| NCT06034470 | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | active not recruiting | Phase 1 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT02506933 | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | active not recruiting | Phase 2 | 102 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05362773 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | active not recruiting | Phase 1 | 130 | MacroGenicsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04603001 | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | active not recruiting | Phase 1 | 260 | Eli Lilly and CompanyINDUSTRY | 12 | Jul 22, 2026 | clinicaltrials |
| NCT05143840 | Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase(ALERTCML) | active not recruiting | Phase 2 | 100 | University of Alabama at BirminghamOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03739502 | A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant(HBO-UBC) | active not recruiting | Phase 2 | 64 | University of RochesterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03817398 | Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia | active not recruiting | Phase 2 | 110 | Children's Oncology GroupNETWORK | 4 | Jul 16, 2026 | clinicaltrials |
| NCT03862157 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04062266 | AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04231851 | CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia | active not recruiting | Phase 2 | 30 | University of California, IrvineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05233618 | Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) | active not recruiting | Phase 1 | 44 | Karen Ballen, MDOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03843528 | Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | active not recruiting | Phase 1 | 15 | Johns Hopkins All Children's HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT03399773 | Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes | active not recruiting | Phase 2 | 31 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT02935361 | Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | active not recruiting | Phase 1 / Phase 2 | 33 | University of Southern CaliforniaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05139004 | 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | active not recruiting | Phase 1 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT00658814 | Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | active not recruiting | Phase 2 | 133 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2026 | clinicaltrials |
| NCT00710892 | CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene(CASPALLO) | active not recruiting | Phase 1 | 10 | Baylor College of MedicineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT01494103 | Administration of Donor T Cells With the Caspase-9 Suicide Gene(DOTTI) | active not recruiting | Phase 1 | 15 | Baylor College of MedicineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02094794 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML | active not recruiting | Phase 2 | 108 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04802161 | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02724163 | International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia(Myechild01) | active not recruiting | Phase 3 | 700 | University of BirminghamOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT03173248 | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation(AGILE) | active not recruiting | Phase 3 | 146 | Institut de Recherches Internationales ServierOTHER | 20 | Jun 29, 2026 | clinicaltrials |
| NCT03289910 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03709758 | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML | active not recruiting | Phase 1 | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06786897 | Expectations of Patients in Palliative Situation(ERAPH) | active not recruiting | — | 37 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04668885 | CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS | active not recruiting | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy(Viale-a) | active not recruiting | Phase 3 | 443 | AbbVieINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 24, 2026source: clinicaltrials